Update on the Center for Recombinant Gamete Contraceptive Vaccinogens.
The overall goal of the Center for Recombinant Gamete Contraceptive Vaccinogens is to develop a contraceptive vaccine which will induce antibodies in the female reproductive tract at sufficient levels to block fertilization. It is envisioned that antibodies developed by this vaccine will act to agglutinate, immobilize or coat either the egg or the sperm in the oviduct, uterus, cervix or vagina. Thus, the vaccine will exert its effects before the fertilization event, as a "prefertilization contraceptive." The Center has focused its activities over the past 4 years on four areas: 1) sperm antigens: the identification and characterization of novel sperm surface molecules which are attractive candidates for inclusion in a vaccine; 2) zona antigens: the identification of synthetic peptides derived from the zona pellucida which possess contraceptive potential without adverse pathology; 3) oral vaccine delivery: the development of live Salmonella vectors which deliver vaccine antigens through the oral route and which will stimulate secretory immunity in the female reproductive tract; and 4) animal testing: the testing of vaccine formulations in in vitro fertilization models, in small animals, in monkeys and in baboons. In addition, preparations for human testing are underway through preparation of an Investigational New Drug Application to begin Phase I human trials of a LDH-C4 peptide vaccine.
Herr
J C
JC
Department of Cell Biology, University of Virginia, Charlottesville 22908, USA.
D000818:Animals; D000941:Antigens / Q000276:immunology*; D003269:Contraception, Immunologic / Q000379:methods*; D005260:Female; D005854:Germ Cells / Q000276:immunology*; D006801:Humans; D008297:Male; D011817:Rabbits; D014614:Vaccines, Synthetic / Q000627:therapeutic use*
D000941:Antigens; D014614:Vaccines, Synthetic